Pharmaceutical

Dyadic and bYoRNA Announce a Collaboration Targeting the Production of Abundant, Low-Cost mRNA From C1-Cells

JUPITER, Fla. and PARIS, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”) (NASDAQ: DYAI) and bYoRNA SAS ("bYoRNA")…

9 months ago

LIXTE Appoints Bas van der Baan as President and Chief Executive Officer

Lixte Biotechnology Holdings, Inc. Bas van der Baan, Newly Appointed President, CEO, Vice Chairman, LIXTE Biotechnology HoldingsBiotechnology Veteran Bas van…

9 months ago

Ambrx to Host KOL Event Discussing ARX517 Data Presented at ESMO Congress 2023

In-person event and virtual webcast to be held on Sunday, October 22, 2023 at 8:00pm CEST / 2:00pm ETSAN DIEGO,…

9 months ago

Lucy Scientific Discovery (NASDAQ: LSDI) Acquisitions Create ‘Golden Opportunity’ for Growth, Success

NEW YORK, Sept. 26, 2023 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Lucy Scientific Discovery (NASDAQ: LSDI) announces the availability of a broadcast…

9 months ago

CorMedix Inc. to Present at the Cantor Fitzgerald Global Healthcare Conference

BERKELEY HEIGHTS, N.J., Sept. 26, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and…

9 months ago

Sharps Technology Signs Asset Purchase Agreement to Acquire InjectEZ Specialty Copolymer Syringe Manufacturing Facility and a 10-Year Purchase Agreement for Over $400 Million from Nephron Pharmaceuticals

$50 Million acquisition of InjectEZ strengthens manufacturing capacity and establishes Sharps’ leading position in the specialized copolymer prefillable syringe system…

9 months ago

Panbela Announces Issuance of New Patent in China for Claims of a Novel Process for the Production of SBP-101

Patent developed in collaboration with Syngene International Ltd.MINNEAPOLIS, Sept. 26, 2023 (GLOBE NEWSWIRE) --  (Nasdaq: PBLA), a clinical-stage biopharmaceutical company…

9 months ago

Phathom Pharmaceuticals Announces Vonoprazan NDA Submission for Non-Erosive GERD

Submission based on positive results from Phase 3 PHALCON-NERD-301 in which vonoprazan 10 mg and 20 mg controlled heartburn symptoms…

9 months ago

Sensus Healthcare to Showcase its Full Line of Cutting-Edge Superficial Radiotherapy Devices for the Treatment of Non-melanoma Skin Cancer at ASTRO 2023 in San Diego

BOCA RATON, Fla, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in…

9 months ago